OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
James J. Harding, Sarina A. Piha‐Paul, Ronak Shah, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 49
James J. Harding, Sarina A. Piha‐Paul, Ronak Shah, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 49
Showing 1-25 of 49 citing articles:
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
James J. Harding, Jia Fan, Do‐Youn Oh, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 7, pp. 772-782
Open Access | Times Cited: 116
James J. Harding, Jia Fan, Do‐Youn Oh, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 7, pp. 772-782
Open Access | Times Cited: 116
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M.F. Mosele, C. Benedikt Westphalen, A Stenzinger, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 588-606
Open Access | Times Cited: 80
M.F. Mosele, C. Benedikt Westphalen, A Stenzinger, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 588-606
Open Access | Times Cited: 80
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 36, pp. 5569-5578
Open Access | Times Cited: 47
Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 36, pp. 5569-5578
Open Access | Times Cited: 47
Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives
B. Ten Haaft, Manuel Pedregal, J Prato, et al.
European Journal of Cancer (2024) Vol. 199, pp. 113564-113564
Open Access | Times Cited: 19
B. Ten Haaft, Manuel Pedregal, J Prato, et al.
European Journal of Cancer (2024) Vol. 199, pp. 113564-113564
Open Access | Times Cited: 19
HER2-targeted therapies beyond breast cancer — an update
Jeesun Yoon, Do‐Youn Oh
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 9, pp. 675-700
Closed Access | Times Cited: 15
Jeesun Yoon, Do‐Youn Oh
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 9, pp. 675-700
Closed Access | Times Cited: 15
Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma
Julien Caldéraro, Narmin Ghaffari Laleh, Qinghe Zeng, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 26
Julien Caldéraro, Narmin Ghaffari Laleh, Qinghe Zeng, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 26
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
Lorenza Rimassa, Ángela Lamarca, Grainne M. O’Kane, et al.
The Lancet Regional Health - Europe (2025) Vol. 50, pp. 101170-101170
Open Access | Times Cited: 1
Lorenza Rimassa, Ángela Lamarca, Grainne M. O’Kane, et al.
The Lancet Regional Health - Europe (2025) Vol. 50, pp. 101170-101170
Open Access | Times Cited: 1
Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma
Jiajia Du, Xing Lv, Zunyi Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21
Jiajia Du, Xing Lv, Zunyi Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21
Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB)
Vikas Ostwal, Sarika Mandavkar, Prabhat Bhargava, et al.
Journal of Clinical Oncology (2023) Vol. 42, Iss. 7, pp. 800-807
Closed Access | Times Cited: 16
Vikas Ostwal, Sarika Mandavkar, Prabhat Bhargava, et al.
Journal of Clinical Oncology (2023) Vol. 42, Iss. 7, pp. 800-807
Closed Access | Times Cited: 16
Unresectable biliary tract cancer: Current and future systemic therapy
Danmei Zhang, Klara Dorman, C. Benedikt Westphalen, et al.
European Journal of Cancer (2024) Vol. 203, pp. 114046-114046
Open Access | Times Cited: 7
Danmei Zhang, Klara Dorman, C. Benedikt Westphalen, et al.
European Journal of Cancer (2024) Vol. 203, pp. 114046-114046
Open Access | Times Cited: 7
Gallbladder cancer: surgical treatment, immunotherapy, and targeted therapy
Yanjun Sun, Jun-feng Gong, Zhuang Li, et al.
Postgraduate Medicine (2024) Vol. 136, Iss. 3, pp. 278-291
Closed Access | Times Cited: 6
Yanjun Sun, Jun-feng Gong, Zhuang Li, et al.
Postgraduate Medicine (2024) Vol. 136, Iss. 3, pp. 278-291
Closed Access | Times Cited: 6
New systemic treatment options for advanced cholangiocarcinoma
Valentina Zanuso, Giulia Tesini, Elena Valenzi, et al.
Journal of Liver Cancer (2024) Vol. 24, Iss. 2, pp. 155-170
Open Access | Times Cited: 4
Valentina Zanuso, Giulia Tesini, Elena Valenzi, et al.
Journal of Liver Cancer (2024) Vol. 24, Iss. 2, pp. 155-170
Open Access | Times Cited: 4
HER2-Targeted Therapies: Unraveling Their Role in Biliary Tract Cancers
Charalampos Theocharopoulos, Ioannis A. Ziogas, Benedetto Mungo, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 208, pp. 104655-104655
Closed Access
Charalampos Theocharopoulos, Ioannis A. Ziogas, Benedetto Mungo, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 208, pp. 104655-104655
Closed Access
S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
Sabrina Groß, Michael Bitzer, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 02, pp. e82-e158
Closed Access
Sabrina Groß, Michael Bitzer, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 02, pp. e82-e158
Closed Access
Current status and prospects of targeted therapy for cholangiocarcinoma based on molecular characteristics
Xiaoqiang Cui, Teng Huang, Tianyi Jiang, et al.
Cancer Letters (2025) Vol. 614, pp. 217540-217540
Closed Access
Xiaoqiang Cui, Teng Huang, Tianyi Jiang, et al.
Cancer Letters (2025) Vol. 614, pp. 217540-217540
Closed Access
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions
Silvia Camera, Federico Rossari, Silvia Foti, et al.
Targeted Oncology (2025)
Closed Access
Silvia Camera, Federico Rossari, Silvia Foti, et al.
Targeted Oncology (2025)
Closed Access
Tucatinib in the treatment of HER2-overexpressing gastrointestinal cancers: current insights and future prospects
Celine Hoyek, Binbin Zheng-Lin, Jeremy Jones, et al.
Expert Opinion on Investigational Drugs (2025), pp. 1-8
Closed Access
Celine Hoyek, Binbin Zheng-Lin, Jeremy Jones, et al.
Expert Opinion on Investigational Drugs (2025), pp. 1-8
Closed Access
S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Langversion
Michael Bitzer, Sabrina Groß, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 03, pp. e159-e260
Closed Access
Michael Bitzer, Sabrina Groß, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 03, pp. e159-e260
Closed Access
Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study
Dan Liu, Jifang Gong, Jian Li, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Dan Liu, Jifang Gong, Jian Li, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Targeting regulated cell death: Apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis in anticancer immunity
Ziyu Guo, Yihuang Liu, Danyao Chen, et al.
Journal of Translational Internal Medicine (2025) Vol. 13, Iss. 1, pp. 10-32
Closed Access
Ziyu Guo, Yihuang Liu, Danyao Chen, et al.
Journal of Translational Internal Medicine (2025) Vol. 13, Iss. 1, pp. 10-32
Closed Access
Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine
Takafumi Mie, Takashi Sasaki, Takeshi Okamoto, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 879-879
Open Access | Times Cited: 3
Takafumi Mie, Takashi Sasaki, Takeshi Okamoto, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 879-879
Open Access | Times Cited: 3
Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis
Marit M. Grimsrud, Michael Förster, Benjamin Goeppert, et al.
Hepatology Communications (2024) Vol. 8, Iss. 7
Open Access | Times Cited: 3
Marit M. Grimsrud, Michael Förster, Benjamin Goeppert, et al.
Hepatology Communications (2024) Vol. 8, Iss. 7
Open Access | Times Cited: 3
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Timothy Lewis Cannon, Michael Rothe, Pam K. Mangat, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 27, pp. 3228-3237
Closed Access | Times Cited: 2
Timothy Lewis Cannon, Michael Rothe, Pam K. Mangat, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 27, pp. 3228-3237
Closed Access | Times Cited: 2
Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations
Padmini Manrai, Austin McHenry, Tong Sun, et al.
International Journal of Gynecological Pathology (2024)
Closed Access | Times Cited: 2
Padmini Manrai, Austin McHenry, Tong Sun, et al.
International Journal of Gynecological Pathology (2024)
Closed Access | Times Cited: 2
Management of intrahepatic and perihilar cholangiocarcinomas: Guidelines of the French Association for the Study of the Liver (AFEF )
Cindy Neuzillet, Marie Decraecker, Hélène Larrue, et al.
Liver International (2024) Vol. 44, Iss. 10, pp. 2517-2537
Open Access | Times Cited: 2
Cindy Neuzillet, Marie Decraecker, Hélène Larrue, et al.
Liver International (2024) Vol. 44, Iss. 10, pp. 2517-2537
Open Access | Times Cited: 2
